RU2000100032A - DERIVATIVES (IMIDAZOL-5-IL) METHYL-2-QUINOLINON AS AN INHIBITOR PROLIFERATION OF SMOOTH MUSCLE CELLS - Google Patents
DERIVATIVES (IMIDAZOL-5-IL) METHYL-2-QUINOLINON AS AN INHIBITOR PROLIFERATION OF SMOOTH MUSCLE CELLSInfo
- Publication number
- RU2000100032A RU2000100032A RU2000100032/14A RU2000100032A RU2000100032A RU 2000100032 A RU2000100032 A RU 2000100032A RU 2000100032/14 A RU2000100032/14 A RU 2000100032/14A RU 2000100032 A RU2000100032 A RU 2000100032A RU 2000100032 A RU2000100032 A RU 2000100032A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- hydrogen
- alkyloxy
- alk
- formula
- Prior art date
Links
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 title claims 4
- 230000035755 proliferation Effects 0.000 title claims 4
- 230000002401 inhibitory effect Effects 0.000 title claims 3
- POYSUXIHCXBJPN-UHFFFAOYSA-N 3-methylquinolin-2(1H)-one Chemical compound C1=CC=C2NC(=O)C(C)=CC2=C1 POYSUXIHCXBJPN-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 128
- 229910052739 hydrogen Inorganic materials 0.000 claims 39
- 239000001257 hydrogen Substances 0.000 claims 39
- 150000002431 hydrogen Chemical class 0.000 claims 34
- 125000003545 alkoxy group Chemical group 0.000 claims 32
- 229910052736 halogen Inorganic materials 0.000 claims 16
- -1 hydroxycarbonyl Chemical group 0.000 claims 15
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 12
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 11
- 150000001875 compounds Chemical class 0.000 claims 10
- 230000002792 vascular Effects 0.000 claims 10
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 230000002062 proliferating Effects 0.000 claims 8
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 4
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 200000000008 restenosis Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 125000004951 trihalomethoxy group Chemical group 0.000 claims 4
- 125000004953 trihalomethyl group Chemical group 0.000 claims 4
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 3
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 3
- 150000003254 radicals Chemical class 0.000 claims 3
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 210000004351 Coronary Vessels Anatomy 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000001320 atherosclerosis Diseases 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 238000009776 industrial production Methods 0.000 claims 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 229910052717 sulfur Chemical group 0.000 claims 2
- 239000011593 sulfur Chemical group 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Claims (19)
его стереоизомерной формы и его фармацевтически приемлемой кислотной или основной аддитивной соли, где пунктирная линия обозначает возможную связь;
Х обозначает кислород или серу;
R1 обозначает водород, C1-12алкил, Аr1, Ar2С1-6алкил, хинолинилС1-6алкил, пиридилС1-6алкил, гидроксиС1-6алкил, С1-6алкилоксиС1-6алкил, моно- или ди(С1-6алкил)аминоС1-6алкил, аминoС1-6алкил, или радикал формулы -Alk1-C(= O)-R9, -Alk1-S(О)-R9 или -Alk1-S(O)2-R9, где Alk1 обозначает С1-6алкандиил;
R9 обозначает гидрокси, С1-6алкил, С1-6алкилокси, амино, С1-8алкиламино или С1-6алкиламино, замещенный С1-6алкилоксикарбонилом;
каждый из R2, R3 и R16 независимо обозначает водород, гидрокси, галоген, циано, С1-6алкил, С1-6алкилокси, гидроксиC1-6алкилокси, С1-6алкилоксиС1-6алкилокси, аминоС1-6алкилокси, моно- или ди(С1-6алкил)аминоС1-6алкилокси, Аr1, Аr2С1-6алкил, Аr2окси, Аr2С1-6алкилокси, гидроксикарбонил, С1-6алкилоксикарбонил, тригалоидметил, тригалоидметокси, С2-6алкенил, 4,4-диметилоксазолил; или,
когда соседние R2 и R3, взятые вместе, могут образовывать двухвалентный радикал формулы
-О-СH2-О- (а-1),
-O-СH2-СH2-O- (а-2),
-O-СН=СН- (а-3),
-O-СH2-СH2- (а-4),
-O-СH2-СH2-СH2- (а-5)
или
-СН=СН-СН=СН- (а-6);
каждый из R4 и R5 независимо обозначает водород, галоген, Аr1, С1-6алкил, гидроксиС1-6алкил, С1-6алкилоксиС1-6алкил, С1-6алкилокси, С1-6алкилтио, амино, гидроксикарбонил, С1-6алкилоксикарбонил, С1-6алкилS(О)С1-6алкил или С1-6алкилS(О)2С1-6алкил;
каждый из R6 и R7 независимо обозначает водород, галоген, циано, С1-6алкил, С1-6алкилокси, Ar2окcи, тригалоидметил, С1-6алкилтио, ди(С1-6алкил)амино или,
когда соседние R6 и R7 вместе, могут образовывать двухвалентный радикал формулы
-О-СН2-О- (с-1)
или
-СН=СН-СН=СН- (с-2);
R8 обозначает водород, С1-6алкил, циано, гидроксикарбонил, С1-6алкилоксикарбонил, С1-6алкилкарбонилС1-6алкил, цианоС1-6алкил, С1-6алкилоксикарбонилС1-6алкил, карбоксиС1-6алкил, гидроксиС1-6алкил, аминоС1-6алкил, моно- или ди(С1-6алкил)аминоС1-6алкил, имидазолил, галоид С1-6алкил, С1-6алкилоксиС1-6алкил, аминокарбонилС1-6алкил или радикал формулы
-O-R10 (b-1),
-S-R10 (b-2),
-N-R11R12 (b-3),
где R10 обозначает водород, С1-6алкил, С1-6алкилкарбонил, Ar1, Ar2С1-6алкил, С1-6алкилоксикарбонилС1-6алкил или радикал формулы -Alk2-OR13 или Alk2-NR14R15;
R11 обозначает водород, С1-12алкил, Аr1 или Ar2С1-6алкил;
R12 обозначает водород, С1-6алкил, С1-16алкилкарбонил, С1-6алкилоксикарбонил, С1-6алкиламинокарбонил, Аr1, Ar2С1-6алкил, С1-6алкилкарбонилС1-6алкил, природную аминокислоту, Аr1карбонил, Аr2С1-6алкилкарбонил, аминокарбонилкарбонил, С1-6алкилоксиС1-6алкилкарбонил, гидрокси, С1-6алкилокси, аминокарбонил, ди(С1-6алкил) аминоС1-6алкилкарбонил, амино, С1-6алкиламино, С1-6алкилкарбониламино или радикал формулы -Alk2-OR13 или -Alk2-NR14R15;
где Alk2 обозначает С1-6алкандиил;
R13 обозначает водород, С1-6алкил, С1-6алкилкарбонил, гидроксиС1-6алкил, Аr1 или Ar2С1-6алкил;
R14 обозначает водород, С1-6алкил, Аr1 или Аr2С1-6алкил;
R15 обозначает водород, С1-6алкил, С1-6алкилкарбонил, Аr1 или Аr2С1-6алкил;
R17 обозначает водород, галоген, циано, С1-6алкил, С1-6алкилоксикарбонил, Аr1;
R18 обозначает водород, С1-6алкил, С1-6алкилокси или галоген;
R19 обозначает водород или С1-6алкил;
Аr1 обозначает фенил или замещенный С1-6алкилом, гидрокси, амино, С1-6алкилокси или галогеном фенил; и
Аr2 обозначает фенил или замещенный С1-6алкилом, гидрокси, амино, С1-6алкилокси или галогеном фенил.1. A method of treating vascular proliferative disorders in warm-blooded animals, which comprises administering said warm-blooded prophylactically or therapeutically effective amount of a compound of formula I,
its stereoisomeric form and its pharmaceutically acceptable acid or base addition salt, where the dotted line indicates a possible bond;
X is oxygen or sulfur;
R 1 is hydrogen, C 1-12 alkyl, Ar 1 , Ar 2 C 1-6 alkyl, quinolinyl C 1-6 alkyl, pyridyl C 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkyloxyC 1-6 alkyl, mono- or di (C 1-6 alkyl) aminoC 1-6 alkyl, aminoC 1-6 alkyl, or a radical of the formula -Alk 1 -C (= O) -R 9 , -Alk 1 -S (O) -R 9 or -Alk 1 -S (O) 2 -R 9 , where Alk 1 is C 1-6 alkanediyl;
R 9 is hydroxy, C 1-6 alkyl, C 1-6 alkyloxy, amino, C 1-8 alkylamino or C 1-6 alkylamino substituted with C 1-6 alkyloxycarbonyl;
each of R 2 , R 3 and R 16 independently denotes hydrogen, hydroxy, halogen, cyano, C 1-6 alkyl, C 1-6 alkyloxy, hydroxyC 1-6 alkyloxy, C 1-6 alkyloxyC 1-6 alkyloxy, aminoC 1 -6 alkyloxy, mono- or di (C 1-6 alkyl) aminoC 1-6 alkyloxy, Ar 1 , Ar 2 C 1-6 alkyl, Ar 2 oxy, Ar 2 C 1-6 alkyloxy, hydroxycarbonyl, C 1-6 alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C 2-6 alkenyl, 4,4-dimethyloxazolyl; or,
when neighboring R 2 and R 3 taken together can form a bivalent radical of the formula
-O-CH 2 -O- (a-1),
—O — CH 2 —CH 2 —O— (a-2),
-O-CH = CH- (a-3),
—O — CH 2 —CH 2 - (a-4),
-O-CH 2 -CH 2 -CH 2 - (a-5)
or
-CH = CH-CH = CH- (a-6);
each of R 4 and R 5 independently represents hydrogen, halogen, Ar 1 , C 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkyloxyC 1-6 alkyl, C 1-6 alkyloxy, C 1-6 alkylthio, amino, hydroxycarbonyl, C 1-6 alkyloxycarbonyl, C 1-6 alkylS (O) C 1-6 alkyl or C 1-6 alkylS (O) 2 C 1-6 alkyl;
each of R 6 and R 7 is independently hydrogen, halogen, cyano, C 1-6 alkyl, C 1-6 alkyloxy, Ar 2 oxyl, trihalomethyl, C 1-6 alkylthio, di (C 1-6 alkyl) amino or,
when neighboring R 6 and R 7 together, can form a bivalent radical of the formula
-O-CH 2 -O- (s-1)
or
-CH = CH-CH = CH- (s-2);
R 8 is hydrogen, C 1-6 alkyl, cyano, hydroxycarbonyl, C 1-6 alkyloxycarbonyl, C 1-6 alkylcarbonylC 1-6 alkyl, cyanoC 1-6 alkyl, C 1-6 alkyloxycarbonylC 1-6 alkyl, carboxyC 1- 6 alkyl, hydroxyC 1-6 alkyl, aminoC 1-6 alkyl, mono- or di (C 1-6 alkyl) aminoC 1-6 alkyl, imidazolyl, halo C 1-6 alkyl, C 1-6 alkyloxyC 1-6 alkyl , aminocarbonyl 1-6 alkyl or a radical of formula
-OR 10 (b-1),
-SR 10 (b-2),
—NR 11 R 12 (b-3),
where R 10 denotes hydrogen, C 1-6 alkyl, C 1-6 alkylcarbonyl, Ar 1 , Ar 2 C 1-6 alkyl, C 1-6 alkyloxycarbonylC 1-6 alkyl or a radical of the formula -Alk 2 -OR 13 or Alk 2 -NR 14 R 15 ;
R 11 is hydrogen, C 1-12 alkyl, Ar 1 or Ar 2 C 1-6 alkyl;
R 12 is hydrogen, C 1-6 alkyl, C 1-16 alkylcarbonyl, C 1-6 alkyloxycarbonyl, C 1-6 alkylaminocarbonyl, Ar 1 , Ar 2 C 1-6 alkyl, C 1-6 alkylcarbonylC 1-6 alkyl, natural amino acid, Ar 1 carbonyl, Ar 2 C 1-6 alkylcarbonyl, aminocarbonylcarbonyl, C 1-6 alkyloxyC 1-6 alkylcarbonyl, hydroxy, C 1-6 alkyloxy, aminocarbonyl, di (C 1-6 alkyl) aminoC 1-6 alkylcarbonyl , amino, C 1-6 alkylamino, C 1-6 alkylcarbonylamino or a radical of the formula -Alk 2 -OR 13 or -Alk 2 -NR 14 R 15 ;
where Alk 2 stands for C 1-6 alkanediyl;
R 13 is hydrogen, C 1-6 alkyl, C 1-6 alkylcarbonyl, hydroxyC 1-6 alkyl, Ar 1 or Ar 2 C 1-6 alkyl;
R 14 is hydrogen, C 1-6 alkyl, Ar 1 or Ar 2 C 1-6 alkyl;
R 15 is hydrogen, C 1-6 alkyl, C 1-6 alkylcarbonyl, Ar 1 or Ar 2 C 1-6 alkyl;
R 17 is hydrogen, halogen, cyano, C 1-6 alkyl, C 1-6 alkyloxycarbonyl, Ar 1 ;
R 18 is hydrogen, C 1-6 alkyl, C 1-6 alkyloxy or halogen;
R 19 is hydrogen or C 1-6 alkyl;
Ar 1 is phenyl or C 1-6 alkyl, hydroxy, amino, C 1-6 alkyloxy or halogen phenyl; and
Ar 2 is phenyl or C 1-6 alkyl, hydroxy, amino, C 1-6 alkyloxy or halogen phenyl.
его стереоизомерной формы и его фармацевтически приемлемой кислотной или основной аддитивной соли, где пунктирная линия обозначает возможную связь; Х обозначает кислород или серу; R1 обозначает водород, С1-12алкил, Аr1, Аr2С1-6алкил, хинолинилС1-6алкил, пиридилС1-6алкил, гидроксиС1-6алкил, С1-6алкилоксиС1-6алкил, моно- или ди(С1-6алкил)аминоС1-6алкил, аминоС1-6алкил, или радикал формулы -Alk1-C(= O)-R9, -Alk1-S(O)-R9 или -Alk1-S(О)2-R9, где Alk1 обозначает С1-6алкандиил, R9 обозначает гидрокси, С1-6алкил, С1-6алкилокси, амино, С1-8алкиламино или С1-8алкиламино, замещенный С1-6алкилоксикарбонилом; каждый из R2, R3, R16 независимо обозначает водород, гидрокси, галоген, циано, С1-6алкил, С1-6алкилокси, гидроксиС1-6алкилокси, С1-6алкилоксиС1-6алкилокси, аминоС1-6алкилокси, моно- или ди(С1-6алкил)аминоС1-6алкилокси, Аr1, Аr2С1-6алкил, Аr2окси, Аr2С1-6алкилокси, гидроксикарбонил, С1-6алкилоксикарбонил, тригалоидметил, тригалоидметокси, С2-6алкенил, 4,4-диметилоксазолил; или, когда соседние R2 и R3, взятые вместе, могут образовывать двухвалентный радикал формулы
-O-СН2-О- (а-1),
-О-СН2-СН2-О- (а-2),
-O-СН=СН- (а-3),
-O-СН2-СН2- (а-4),
-O-СН2-СН2-СН2- (а-5)
или
-СН=СН-СН=СН- (а-6);
каждый из R4 и R5 независимо обозначает водород, галоген, Аr1, C1-6алкил, гидроксиC1-6алкил, C1-6алкилоксиC1-6алкил, C1-6алкилокси, C1-6алкилтио, амино, гидроксикарбонил, C1-6алкилоксикарбонил, C1-6алкилS(О)C1-6алкил или C1-6алкилS(О)2C1-6алкил; каждый из R6 и R7 независимо обозначает водород, галоген, циано, C1-6алкил, C1-6алкилокси, Ar2окcи, тригалоидметил, C1-6алкилтио, ди(C1-6алкил)амино или, когда соседние R6 и R7 вместе, могут образовывать двухвалентный радикал формулы
-О-СН2-О- (с-1)
или
-СН=СН-СН=СН- (с-2);
R8 обозначает водород, C1-6алкил, циано, гидроксикарбонил, C1-6алкилоксикарбонил, C1-6алкилкарбонилC1-6алкил, цианоC1-6алкил, C1-6алкилоксикарбонилC1-6алкил, карбоксиC1-6алкил, гидроксиC1-6алкил, аминоC1-6алкил, моно- или ди(C1-6алкил)аминоC1-6алкил, имидазолил, галоидC1-6алкил, C1-6алкилоксиC1-6алкил, аминокарбонилC1-6алкил или радикал формулы
-O-R10 (b-1),
-S-R10 (b-2),
-N-R11R12 (b-3),
где R10 обозначает водород, C1-6алкил, C1-6алкилкарбонил, Аr1, Аr2C1-6алкил, C1-6алкилоксикарбонилC1-6алкил или радикал формулы -Alk2-OR13 или Alk2-NR14R15; R11 обозначает водород, C1-12алкил, Аr1 или Ar2C1-6алкил; R12 обозначает водород, C1-6алкил, C1-16алкилкарбонил, C1-6алкилоксикарбонил, C1-6алкиламинокарбонил, Аr1, Аr2C1-6алкил, C1-6алкилкарбонилC1-6алкил, природную аминокислоту, Аr1карбонил, Аr2C1-6алкилкарбонил, аминокарбонилкарбонил, C1-6алкилоксиC1-6алкилкарбонил, гидрокси, C1-6алкилокси, аминокарбонил, ди(C1-6алкил)аминоC1-6алкилкарбонил, амино, C1-6алкиламино, C1-6алкилкарбониламино или радикал формулы -Alk2-OR13 или -Alk2-NR14R15; где Alk2 обозначает C1-6алкандиил; R13 обозначает водород, C1-6алкил, C1-6алкилкарбонил, гидроксиC1-6алкил, Аr1 или Аr2C1-6алкил; R14 обозначает водород, C1-6алкил, Аr1 или Аr2C1-6алкил; R15 обозначает водород, C1-6алкил, C1-6алкилкарбонил, Аr1 или Ar2C1-6алкил; R17 обозначает водород, галоген, циано, C1-6алкил, C1-6алкилоксикарбонил, Аr1; R18 обозначает водород, C1-6алкил, C1-6алкилокси или галоген; R19 обозначает водород или C1-6алкил; Аr1 обозначает фенил или замещенный C1-6алкилом, гидрокси, амино, C1-6алкилокси или галогеном фенил; и Аr2 обозначает фенил или замещенный C1-6алкилом, гидрокси, амино, C1-6алкилокси или галогеном фенил; для промышленного получения лекарственного препарата для профилактики или лечения васкулярных пролиферативных нарушений.11. The use of the compounds of formula (I)
its stereoisomeric form and its pharmaceutically acceptable acid or base addition salt, where the dotted line indicates a possible bond; X is oxygen or sulfur; R 1 is hydrogen, C 1-12 alkyl, Ar 1 , Ar 2 C 1-6 alkyl, quinolinyl C 1-6 alkyl, pyridyl C 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkyloxyC 1-6 alkyl, mono- or di (C 1-6 alkyl) aminoC 1-6 alkyl, aminoC 1-6 alkyl, or a radical of the formula -Alk 1 -C (= O) -R 9 , -Alk 1 -S (O) -R 9 or -Alk 1 -S (O) 2 -R 9 , where Alk 1 denotes C 1-6 alkanediyl, R 9 denotes hydroxy, C 1-6 alkyl, C 1-6 alkyloxy, amino, C 1-8 alkylamino or C 1-8 alkylamino substituted with C 1-6 alkyloxycarbonyl; each of R 2 , R 3 , R 16 independently denotes hydrogen, hydroxy, halogen, cyano, C 1-6 alkyl, C 1-6 alkyloxy, hydroxyC 1-6 alkyloxy, C 1-6 alkyloxyC 1-6 alkyloxy, aminoC 1 -6 alkyloxy, mono- or di (C 1-6 alkyl) aminoC 1-6 alkyloxy, Ar 1 , Ar 2 C 1-6 alkyl, Ar 2 oxy, Ar 2 C 1-6 alkyloxy, hydroxycarbonyl, C 1-6 alkyloxycarbonyl, trihalomethyl, trihalomethoxy, C 2-6 alkenyl, 4,4-dimethyloxazolyl; or when neighboring R 2 and R 3 taken together can form a bivalent radical of the formula
-O-CH 2 -O- (a-1),
—O — CH 2 —CH 2 —O— (a-2),
-O-CH = CH- (a-3),
—O — CH 2 —CH 2 - (a-4),
—O — CH 2 —CH 2 —CH 2 - (a-5)
or
-CH = CH-CH = CH- (a-6);
each of R 4 and R 5 independently represents hydrogen, halogen, Ar 1 , C 1-6 alkyl, hydroxyC 1-6 alkyl, C 1-6 alkyloxyC 1-6 alkyl, C 1-6 alkyloxy, C 1-6 alkylthio, amino, hydroxycarbonyl, C 1-6 alkyloxycarbonyl, C 1-6 alkylS (O) C 1-6 alkyl or C 1-6 alkylS (O) 2 C 1-6 alkyl; each of R 6 and R 7 independently represents hydrogen, halogen, cyano, C 1-6 alkyl, C 1-6 alkyloxy, Ar 2 hydroxy, trihalomethyl, C 1-6 alkylthio, di (C 1-6 alkyl) amino or, when neighboring R 6 and R 7 together, can form a bivalent radical of the formula
-O-CH 2 -O- (s-1)
or
-CH = CH-CH = CH- (s-2);
R 8 is hydrogen, C 1-6 alkyl, cyano, hydroxycarbonyl, C 1-6 alkyloxycarbonyl, C 1-6 alkylcarbonylC 1-6 alkyl, cyanoC 1-6 alkyl, C 1-6 alkyloxycarbonylC 1-6 alkyl, carboxyC 1- 6 alkyl, hydroxyC 1-6 alkyl, aminoC 1-6 alkyl, mono- or di (C 1-6 alkyl) aminoC 1-6 alkyl, imidazolyl, haloC 1-6 alkyl, C 1-6 alkyloxyC 1-6 alkyl, aminocarbonylC 1-6 alkyl or a radical of formula
-OR 10 (b-1),
-SR 10 (b-2),
—NR 11 R 12 (b-3),
where R 10 denotes hydrogen, C 1-6 alkyl, C 1-6 alkylcarbonyl, Ar 1 , Ar 2 C 1-6 alkyl, C 1-6 alkyloxycarbonyl C 1-6 alkyl or a radical of the formula -Alk 2 -OR 13 or Alk 2 -NR 14 R 15 ; R 11 is hydrogen, C 1-12 alkyl, Ar 1 or Ar 2 C 1-6 alkyl; R 12 is hydrogen, C 1-6 alkyl, C 1-16 alkylcarbonyl, C 1-6 alkyloxycarbonyl, C 1-6 alkylaminocarbonyl, Ar 1 , Ar 2 C 1-6 alkyl, C 1-6 alkylcarbonyl C 1-6 alkyl, natural amino acid, Ar 1 carbonyl, Ar 2 C 1-6 alkylcarbonyl, aminocarbonylcarbonyl, C 1-6 alkyloxyC 1-6 alkylcarbonyl, hydroxy, C 1-6 alkyloxy, aminocarbonyl, di (C 1-6 alkyl) aminoC 1-6 alkylcarbonyl , amino, C 1-6 alkylamino, C 1-6 alkylcarbonylamino or a radical of the formula -Alk 2 -OR 13 or -Alk 2 -NR 14 R 15 ; where Alk 2 stands for C 1-6 alkanediyl; R 13 is hydrogen, C 1-6 alkyl, C 1-6 alkylcarbonyl, hydroxyC 1-6 alkyl, Ar 1 or Ar 2 C 1-6 alkyl; R 14 is hydrogen, C 1-6 alkyl, Ar 1 or Ar 2 C 1-6 alkyl; R 15 is hydrogen, C 1-6 alkyl, C 1-6 alkylcarbonyl, Ar 1 or Ar 2 C 1-6 alkyl; R 17 is hydrogen, halogen, cyano, C 1-6 alkyl, C 1-6 alkyloxycarbonyl, Ar 1 ; R 18 is hydrogen, C 1-6 alkyl, C 1-6 alkyloxy or halogen; R 19 is hydrogen or C 1-6 alkyl; Ar 1 is phenyl or C 1-6 alkyl, hydroxy, amino, C 1-6 alkyloxy or halogen phenyl; and Ar 2 is phenyl or C 1-6 alkyl, hydroxy, amino, C 1-6 alkyloxy or halogen phenyl; for industrial production of a medicinal product for the prevention or treatment of vascular proliferative disorders.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4737697P | 1997-06-02 | 1997-06-02 | |
US60/047,376 | 1997-06-02 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2000100032A true RU2000100032A (en) | 2001-10-10 |
RU2209066C2 RU2209066C2 (en) | 2003-07-27 |
Family
ID=21948611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2000100032/14A RU2209066C2 (en) | 1997-06-02 | 1998-05-25 | Derivatives of (imidazol-5-yl)methyl-2-quinolinone as inhibitors of smooth muscle cells proliferation |
Country Status (22)
Country | Link |
---|---|
US (4) | US6365600B1 (en) |
EP (1) | EP0988038B1 (en) |
JP (1) | JP4209472B2 (en) |
KR (1) | KR100517832B1 (en) |
CN (2) | CN1231215C (en) |
AT (1) | ATE222104T1 (en) |
AU (1) | AU740603B2 (en) |
BR (1) | BR9810423A (en) |
CA (1) | CA2290992C (en) |
DE (1) | DE69807222T2 (en) |
DK (1) | DK0988038T3 (en) |
ES (1) | ES2182327T3 (en) |
HK (2) | HK1025046A1 (en) |
ID (1) | ID24675A (en) |
IL (1) | IL133212A (en) |
NO (1) | NO318834B1 (en) |
NZ (1) | NZ501401A (en) |
PT (1) | PT988038E (en) |
RU (1) | RU2209066C2 (en) |
TR (1) | TR199902923T2 (en) |
WO (1) | WO1998055124A1 (en) |
ZA (1) | ZA984700B (en) |
Families Citing this family (100)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1231215C (en) | 1997-06-02 | 2005-12-14 | 詹森药业有限公司 | (Imidazol-5-yl) methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation |
US20030040790A1 (en) * | 1998-04-15 | 2003-02-27 | Furst Joseph G. | Stent coating |
US20020099438A1 (en) * | 1998-04-15 | 2002-07-25 | Furst Joseph G. | Irradiated stent coating |
US6451812B1 (en) * | 1998-07-06 | 2002-09-17 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors for treating arthropathies |
US8070796B2 (en) | 1998-07-27 | 2011-12-06 | Icon Interventional Systems, Inc. | Thrombosis inhibiting graft |
US7967855B2 (en) | 1998-07-27 | 2011-06-28 | Icon Interventional Systems, Inc. | Coated medical device |
AU4925199A (en) * | 1998-08-27 | 2000-03-21 | Pfizer Products Inc. | Quinolin-2-one derivatives useful as anticancer agents |
IL143859A0 (en) * | 1998-12-23 | 2002-04-21 | Janssen Pharmaceutica Nv | 1,2-annelated quinoline derivatives |
SK11002001A3 (en) | 1999-02-11 | 2002-05-09 | Pfizer Products Inc. | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents |
EP1106612B1 (en) * | 1999-11-30 | 2004-02-11 | Pfizer Products Inc. | Quinoline derivatives useful for inhibiting farnesyl protein transferase |
US6844357B2 (en) * | 2000-05-01 | 2005-01-18 | Pfizer Inc. | Substituted quinolin-2-one derivatives useful as antiproliferative agents |
JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Farnesyl transferase inhibiting 1-2 annelated quinoline enantiomer |
US6605617B2 (en) | 2000-09-11 | 2003-08-12 | Chiron Corporation | Quinolinone derivatives |
FR2813791B1 (en) * | 2000-09-14 | 2004-03-12 | Lafon Labor | USE OF 2- AND 4-QUINOLONES TO INHIBIT INTIMAL NEO-PROLIFERATION |
EP1322636A1 (en) * | 2000-09-25 | 2003-07-02 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6- (substituted phenyl)methyl]-quinoline and quinazoline derivatives |
JP4974439B2 (en) * | 2000-09-25 | 2012-07-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 6-Heterocyclylmethylquinolinone derivatives that inhibit farnesyltransferase |
US7196094B2 (en) | 2000-09-25 | 2007-03-27 | Janssen Pharmaceutica, N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
DE60118225T2 (en) | 2000-09-25 | 2007-05-03 | Janssen Pharmaceutica N.V. | CHINOLIN AND CHINAZOLINE DERIVATIVES AND THEIR USE AS FARNESYL TRANSFERASE INHIBITORS |
ES2328225T3 (en) | 2000-11-21 | 2009-11-11 | Janssen Pharmaceutica Nv | INHIBITING BENZOHETEROCICLIC DERIVATIVES OF THE FARNESIL-TRANSFERASA. |
EP1347966B1 (en) | 2000-12-27 | 2006-03-08 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
EP1408971A4 (en) | 2001-06-21 | 2006-01-25 | Ariad Pharma Inc | Novel quinolines and uses thereof |
US7408063B2 (en) | 2001-12-19 | 2008-08-05 | Janssen Pharmaceutica, N.V. | 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors |
US7354932B2 (en) | 2001-12-21 | 2008-04-08 | Anormed, Inc. | Chemokine receptor binding heterocyclic compounds with enhanced efficacy |
JP4450628B2 (en) | 2002-03-22 | 2010-04-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors |
US7511138B2 (en) | 2002-04-15 | 2009-03-31 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles |
US8016881B2 (en) | 2002-07-31 | 2011-09-13 | Icon Interventional Systems, Inc. | Sutures and surgical staples for anastamoses, wound closures, and surgical closures |
US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
US6638301B1 (en) * | 2002-10-02 | 2003-10-28 | Scimed Life Systems, Inc. | Medical device with radiopacity |
JP2006511616A (en) | 2002-11-13 | 2006-04-06 | カイロン コーポレイション | Methods for treating cancer and related methods |
US20050154451A1 (en) * | 2003-12-18 | 2005-07-14 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
US7211108B2 (en) * | 2004-01-23 | 2007-05-01 | Icon Medical Corp. | Vascular grafts with amphiphilic block copolymer coatings |
KR101150172B1 (en) * | 2004-01-23 | 2012-05-25 | 얀센 파마슈티카 엔.브이. | Substituted quinolines and their use as mycobacterial inhibitors |
US7875624B2 (en) | 2004-02-20 | 2011-01-25 | Novartis Vaccines And Diagnostics, Inc. | Modulating and measuring cellular adhesion |
JP4870660B2 (en) * | 2004-03-15 | 2012-02-08 | アノーメッド インコーポレイティド | CXCR4 antagonist synthesis process |
WO2005089502A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
WO2005089515A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
EP1732549A4 (en) * | 2004-03-18 | 2009-11-11 | Brigham & Womens Hospital | Methods for the treatment of synucleinopathies |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
US20060106060A1 (en) * | 2004-03-18 | 2006-05-18 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies (Lansbury) |
WO2005089518A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Uch-l1 expression and cancer therapy |
US7063720B2 (en) * | 2004-09-14 | 2006-06-20 | The Wallace Enterprises, Inc. | Covered stent with controlled therapeutic agent diffusion |
US20060083770A1 (en) * | 2004-10-15 | 2006-04-20 | Specialty Coating Systems, Inc. | Medical devices and methods of preparation and use |
US20060194821A1 (en) * | 2005-02-18 | 2006-08-31 | The Brigham And Women's Hospital, Inc. | Compounds inhibiting the aggregation of superoxide dismutase-1 |
US20060200048A1 (en) * | 2005-03-03 | 2006-09-07 | Icon Medical Corp. | Removable sheath for device protection |
US9107899B2 (en) | 2005-03-03 | 2015-08-18 | Icon Medical Corporation | Metal alloys for medical devices |
US7540995B2 (en) | 2005-03-03 | 2009-06-02 | Icon Medical Corp. | Process for forming an improved metal alloy stent |
US20060264914A1 (en) * | 2005-03-03 | 2006-11-23 | Icon Medical Corp. | Metal alloys for medical devices |
US8323333B2 (en) * | 2005-03-03 | 2012-12-04 | Icon Medical Corp. | Fragile structure protective coating |
WO2006110197A2 (en) | 2005-03-03 | 2006-10-19 | Icon Medical Corp. | Polymer biodegradable medical device |
US20060201601A1 (en) * | 2005-03-03 | 2006-09-14 | Icon Interventional Systems, Inc. | Flexible markers |
MX2007014782A (en) | 2005-05-23 | 2008-02-19 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4- methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts. |
CA2617213C (en) | 2005-07-29 | 2014-01-28 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
EP2545919A1 (en) | 2005-12-23 | 2013-01-16 | Link Medicine Corporation | Treatment of synucleinopathies |
US20070148390A1 (en) * | 2005-12-27 | 2007-06-28 | Specialty Coating Systems, Inc. | Fluorinated coatings |
ES2382009T3 (en) * | 2006-12-01 | 2012-06-04 | Bristol-Myers Squibb Company | N - ((3-Benzyl) -2,2- (bis-phenyl -) - propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases |
US8053440B2 (en) | 2007-02-01 | 2011-11-08 | Resverlogix Corporation | Compounds for the prevention and treatment of cardiovascular diseases |
ES2390323T3 (en) * | 2007-05-23 | 2012-11-08 | Allergan, Inc. | Therapeutic compounds of ((phenyl) imidazolyl) methylquinolinyl |
US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
PL2346837T3 (en) | 2008-06-26 | 2015-07-31 | Resverlogix Corp | Methods of preparing quinazolinone derivatives |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
BRPI0920927A2 (en) * | 2008-11-13 | 2019-09-24 | Link Medicine Corp | azaquinolinone derivatives and uses thereof |
ES2463097T3 (en) | 2009-01-08 | 2014-05-27 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
EP2408454A2 (en) | 2009-03-18 | 2012-01-25 | Resverlogix Corp. | Novel anti-inflammatory agents |
NZ596117A (en) | 2009-04-22 | 2014-10-31 | Resverlogix Corp | Novel anti-inflammatory agents |
US8398916B2 (en) | 2010-03-04 | 2013-03-19 | Icon Medical Corp. | Method for forming a tubular medical device |
ES2745471T3 (en) | 2011-11-01 | 2020-03-02 | Resverlogix Corp | Oral immediate-release formulations for substituted quinazolinones |
CN104093709B (en) * | 2012-02-13 | 2017-09-22 | 霍夫曼-拉罗奇有限公司 | It is used as the imidazole derivative of aldosterone synthase inhibitors |
KR20150070348A (en) * | 2012-10-16 | 2015-06-24 | 얀센 파마슈티카 엔.브이. | Heteroaryl linked quinolinyl modulators of rorγt |
JP6466335B2 (en) | 2012-10-16 | 2019-02-06 | ヤンセン ファーマシューティカ エヌ.ベー. | ROR-γ-T methylene-linked quinolinyl modulators |
EA201590750A1 (en) | 2012-10-16 | 2015-09-30 | Янссен Фармацевтика Нв | RELATED QUINOLINYL MODULATORS WITH PHENYL |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
US9765039B2 (en) | 2012-11-21 | 2017-09-19 | Zenith Epigenetics Ltd. | Biaryl derivatives as bromodomain inhibitors |
AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
US9624225B2 (en) | 2013-10-15 | 2017-04-18 | Janssen Pharmaceutica Nv | Quinolinyl modulators of RORγt |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
WO2015057629A1 (en) | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | ALKYL LINKED QUINOLINYL MODULATORS OF RORyt |
US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
US11266767B2 (en) | 2014-06-24 | 2022-03-08 | Mirus Llc | Metal alloys for medical devices |
CA2972771A1 (en) * | 2014-12-18 | 2016-06-23 | University Of South Carolina | Suppression of neointimal formation following vascular surgery using cdk8 inhibitors |
CN114984016A (en) | 2015-03-13 | 2022-09-02 | 雷斯韦洛吉克斯公司 | Compositions and methods for treating complement-associated diseases |
HUE054068T2 (en) | 2015-04-21 | 2021-08-30 | Eiger Biopharmaceuticals Inc | Pharmaceutical compositions comprising lonafarnib and ritonavir |
TWI710642B (en) | 2015-08-17 | 2020-11-21 | 美商庫拉腫瘤技術股份有限公司 | Methods of treating cancer patients with farnesyltransferase inhibitors |
US11357742B2 (en) | 2015-12-14 | 2022-06-14 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
EP3389634B1 (en) | 2015-12-14 | 2021-10-06 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
WO2017112894A1 (en) | 2015-12-22 | 2017-06-29 | X4 Pharmaceuticals, Inc. | Methods for treating immunodeficiency disease |
US11766506B2 (en) | 2016-03-04 | 2023-09-26 | Mirus Llc | Stent device for spinal fusion |
CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
CN109641838A (en) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | CXCR4 inhibitor and application thereof |
EP3808748A1 (en) | 2016-06-21 | 2021-04-21 | X4 Pharmaceuticals, Inc. | Substituted piperidines as cxcr4-inhibitors |
WO2017223229A1 (en) | 2016-06-21 | 2017-12-28 | X4 Pharmaceuticals, Inc. | Cxcr4 inhibitors and uses thereof |
EP3534885B1 (en) | 2016-11-03 | 2021-01-20 | Kura Oncology, Inc. | Farnesyltransferase inhibitors for use in treating cancer |
US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
CN110204487B (en) * | 2019-06-21 | 2021-09-28 | 江南大学 | Synthesis method of quinoline derivative |
CN113072490B (en) * | 2021-03-26 | 2022-08-16 | 中国海洋大学 | High-efficiency synthesis method of tipifarnib quinolinone intermediate |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE456347B (en) | 1982-02-09 | 1988-09-26 | Ird Biomaterial Ab | SURFACE MODIFIED SOLID SUBSTRATE AND PROCEDURES FOR PRODUCING THEREOF |
US5213898A (en) | 1989-10-12 | 1993-05-25 | Norsk Hydro A.S. | Process for the preparation of surface modified solid substrates |
US5049403A (en) | 1989-10-12 | 1991-09-17 | Horsk Hydro A.S. | Process for the preparation of surface modified solid substrates |
US5356433A (en) | 1991-08-13 | 1994-10-18 | Cordis Corporation | Biocompatible metal surfaces |
JPH07112930A (en) * | 1993-10-14 | 1995-05-02 | Kyowa Hakko Kogyo Co Ltd | Cell proliferation inhibitor for vascular smooth muscle |
CA2216943C (en) | 1995-04-19 | 2003-06-17 | Schneider (Usa) Inc. | Drug release coated stent |
US5607475A (en) | 1995-08-22 | 1997-03-04 | Medtronic, Inc. | Biocompatible medical article and method |
US5863904A (en) | 1995-09-26 | 1999-01-26 | The University Of Michigan | Methods for treating cancers and restenosis with P21 |
TW349948B (en) * | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
DE69620445T2 (en) * | 1995-12-08 | 2002-12-12 | Janssen Pharmaceutica Nv | (IMIDAZOL-5-YL) METHYL-2-CHINOLINO DERIVATIVES AS A FARNESYL PROTEIN TRANSFERASE INHIBITOR |
CN1231215C (en) | 1997-06-02 | 2005-12-14 | 詹森药业有限公司 | (Imidazol-5-yl) methyl-2-quinolinone derivatives as inhibitors of smooth muscle cell proliferation |
-
1998
- 1998-05-25 CN CNB98805700XA patent/CN1231215C/en not_active Expired - Lifetime
- 1998-05-25 BR BR9810423-3A patent/BR9810423A/en not_active Application Discontinuation
- 1998-05-25 JP JP50144099A patent/JP4209472B2/en not_active Expired - Lifetime
- 1998-05-25 CN CNB2005101163581A patent/CN100525766C/en not_active Expired - Lifetime
- 1998-05-25 EP EP98928332A patent/EP0988038B1/en not_active Expired - Lifetime
- 1998-05-25 IL IL13321298A patent/IL133212A/en not_active IP Right Cessation
- 1998-05-25 NZ NZ501401A patent/NZ501401A/en not_active IP Right Cessation
- 1998-05-25 DK DK98928332T patent/DK0988038T3/en active
- 1998-05-25 AT AT98928332T patent/ATE222104T1/en active
- 1998-05-25 PT PT98928332T patent/PT988038E/en unknown
- 1998-05-25 AU AU80207/98A patent/AU740603B2/en not_active Expired
- 1998-05-25 RU RU2000100032/14A patent/RU2209066C2/en active
- 1998-05-25 KR KR10-1999-7010744A patent/KR100517832B1/en not_active IP Right Cessation
- 1998-05-25 DE DE69807222T patent/DE69807222T2/en not_active Expired - Lifetime
- 1998-05-25 TR TR1999/02923T patent/TR199902923T2/en unknown
- 1998-05-25 CA CA002290992A patent/CA2290992C/en not_active Expired - Lifetime
- 1998-05-25 ES ES98928332T patent/ES2182327T3/en not_active Expired - Lifetime
- 1998-05-25 WO PCT/EP1998/003182 patent/WO1998055124A1/en active IP Right Grant
- 1998-05-28 ID IDW991506A patent/ID24675A/en unknown
- 1998-06-01 ZA ZA9804700A patent/ZA984700B/en unknown
-
1999
- 1999-05-25 US US09/445,009 patent/US6365600B1/en not_active Expired - Lifetime
- 1999-12-01 NO NO19995883A patent/NO318834B1/en not_active IP Right Cessation
-
2000
- 2000-07-08 HK HK00104198A patent/HK1025046A1/en not_active IP Right Cessation
-
2001
- 2001-11-28 US US09/996,147 patent/US6743805B2/en not_active Expired - Lifetime
-
2003
- 2003-06-18 US US10/464,570 patent/US6734194B2/en not_active Expired - Lifetime
-
2004
- 2004-04-14 US US10/823,862 patent/US7253183B2/en not_active Expired - Lifetime
-
2006
- 2006-08-16 HK HK06109112.8A patent/HK1088820A1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2000100032A (en) | DERIVATIVES (IMIDAZOL-5-IL) METHYL-2-QUINOLINON AS AN INHIBITOR PROLIFERATION OF SMOOTH MUSCLE CELLS | |
RU2209066C2 (en) | Derivatives of (imidazol-5-yl)methyl-2-quinolinone as inhibitors of smooth muscle cells proliferation | |
EP1267848B1 (en) | Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer | |
JP2003521509A5 (en) | ||
WO2001064246A2 (en) | Farnesyl protein transferase inhibitor combinations with an her2 antibody | |
EP1162201A3 (en) | Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives | |
KR20010052770A (en) | Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties | |
JP2003525246A (en) | Combination of farnesyl protein transferase inhibitor with platinum compound | |
JP2003521509A (en) | Farnesyl protein transferase inhibitors for the treatment of breast cancer | |
JP2003525234A (en) | Combination of farnesyl protein transferase inhibitor with camptothecin compound | |
JP2003525239A (en) | Combination of farnesyl protein transferase inhibitor with taxane compound | |
JP2003525235A (en) | Combination of a farnesyl protein transferase inhibitor with an antitumor nucleoside derivative | |
US20040157773A1 (en) | Farnesyl protein transferase inhibitors for treating cachexia | |
EP1261348A2 (en) | Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents | |
JP2003525245A (en) | Farnesyl protein transferase inhibitor combination | |
JP2003525236A (en) | Combination of a farnesyl protein transferase inhibitor with vinca alkaloids | |
JP2002504933A (en) | Cell transfer agent used for treatment of skin aging and wounds | |
KR100694004B1 (en) | Use of propiony L-carnitine for the preparation of a medicament capable of inducing apoptosis |